M&A / Deals Gilead Less M&A Happy Now but Door Still Open for ‘Compelling’ Opportunities BioSpaceGilead Sciences has inked three deals this year so far totaling $14.77 billion, a marked escalation of the company's usual M A pace.M&A / DealsRead full story pharminent April 8, 2026 (Last updated: April 8, 2026) BioSpace Gilead Sciences has inked three deals this year so far totaling $14.77 billion, a marked escalation of the company’s usual M A pace. M&A / DealsRead full story Post navigation Previous: Medicare Advantage Insurers Will See Higher Payments as CMS Backs Off a Key Payment UpdateNext: With 3 quick buyouts, Gilead leans into its latest transformation Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026